PL1901729T3 - Formulacje farmaceutyczne inhibitorów hdac - Google Patents
Formulacje farmaceutyczne inhibitorów hdacInfo
- Publication number
- PL1901729T3 PL1901729T3 PL06727086T PL06727086T PL1901729T3 PL 1901729 T3 PL1901729 T3 PL 1901729T3 PL 06727086 T PL06727086 T PL 06727086T PL 06727086 T PL06727086 T PL 06727086T PL 1901729 T3 PL1901729 T3 PL 1901729T3
- Authority
- PL
- Poland
- Prior art keywords
- hdac
- pharmaceutical formulations
- hdac inhibitors
- pertains
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 4
- 108090000353 Histone deacetylase Proteins 0.000 abstract 4
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68121505P | 2005-05-13 | 2005-05-13 | |
| US68123405P | 2005-05-13 | 2005-05-13 | |
| EP06727086A EP1901729B1 (en) | 2005-05-13 | 2006-05-11 | Pharmaceutical formulations of hdac inhibitors |
| PCT/GB2006/001737 WO2006120456A1 (en) | 2005-05-13 | 2006-05-11 | Pharmaceutical formulations of hdac inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1901729T3 true PL1901729T3 (pl) | 2012-07-31 |
Family
ID=36617353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06727086T PL1901729T3 (pl) | 2005-05-13 | 2006-05-11 | Formulacje farmaceutyczne inhibitorów hdac |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8835501B2 (pl) |
| EP (2) | EP2494969B1 (pl) |
| JP (2) | JP5108750B2 (pl) |
| KR (2) | KR101329437B1 (pl) |
| CN (2) | CN102579417B (pl) |
| AT (1) | ATE542527T1 (pl) |
| AU (1) | AU2006245495B2 (pl) |
| BR (1) | BRPI0610128B1 (pl) |
| CA (1) | CA2606598C (pl) |
| CY (1) | CY1112498T1 (pl) |
| DK (2) | DK2494969T3 (pl) |
| EA (2) | EA023400B1 (pl) |
| EC (1) | ECSP078002A (pl) |
| ES (2) | ES2540204T3 (pl) |
| HR (1) | HRP20120341T1 (pl) |
| IL (2) | IL187231A (pl) |
| MX (1) | MX2007013938A (pl) |
| NO (1) | NO339954B1 (pl) |
| NZ (1) | NZ563236A (pl) |
| PL (1) | PL1901729T3 (pl) |
| PT (1) | PT1901729E (pl) |
| RS (1) | RS52214B (pl) |
| SI (1) | SI1901729T1 (pl) |
| UA (1) | UA99810C2 (pl) |
| WO (1) | WO2006120456A1 (pl) |
| ZA (1) | ZA200710313B (pl) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502649A1 (en) | 2005-02-03 | 2012-09-26 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and erlotinib for treating cancer |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| ITRM20070038A1 (it) * | 2007-01-26 | 2008-07-27 | Uni Degli Studi Di Roma La Sapienza | Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico |
| US8946201B2 (en) * | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
| US8642809B2 (en) * | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| AU2009220942B2 (en) * | 2008-03-07 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Methods of treatment employing prolonged continuous infusion of Belinostat |
| CN102159219B (zh) * | 2008-09-16 | 2015-06-24 | 圣路易斯大学 | 提高转化生长因子-β信号发送的方法 |
| CA2740952C (en) * | 2008-10-22 | 2015-12-29 | Ian L. Scott | Compounds for treating ophthalmic diseases and disorders |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2011064663A1 (en) | 2009-11-25 | 2011-06-03 | Festuccia, Claudio | Combination treatment employing belinostat and bicalutamide |
| HUE032100T2 (en) | 2011-03-21 | 2017-08-28 | Valcuria Ab | A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use |
| EP2758052B9 (en) * | 2011-09-18 | 2019-03-27 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
| JP2015504056A (ja) * | 2011-12-29 | 2015-02-05 | ファーマサイクリックス，インク． | ヒストンデアセチラーゼ８の阻害剤としての珪皮酸ヒドロキシアミド |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| MX2016016311A (es) | 2014-06-12 | 2017-10-12 | Univ Notre Dame Du Lac | Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EA201792028A1 (ru) | 2015-03-13 | 2018-04-30 | Форма Терапьютикс, Инк. | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 |
| US11439643B2 (en) | 2015-06-16 | 2022-09-13 | Acrotech Biopharma Inc. | Combination therapy using belinostat and pralatrexate to treat lymphoma |
| CN105481736A (zh) * | 2015-12-28 | 2016-04-13 | 山东大学 | 一种含有苯甘氨酸的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
| CA3015241A1 (en) | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| CA3018923A1 (en) | 2016-03-31 | 2017-10-05 | Midatech Ltd. | Cyclodextrin-panobinostat adduct for treating brain tumours |
| JP2019524879A (ja) * | 2016-07-08 | 2019-09-05 | ラネディス ファーマシューティカルズ リミテッド ライアビリティ カンパニー | リソソーム蓄積症およびその他の単一遺伝子代謝疾患を処置および／または予防するための組成物および方法 |
| CN107625967B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞注射用药物组合物及其制备方法 |
| CN107638571B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞口服药物组合物及其制备方法 |
| WO2018029699A1 (en) * | 2016-08-11 | 2018-02-15 | Msn Research & Development Center | Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof |
| US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| CN106389359B (zh) * | 2016-11-30 | 2019-07-26 | 瑞阳制药有限公司 | 供注射用的贝利司他药物组合物及其制备方法 |
| CN108210501B (zh) * | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| DK3644970T3 (da) * | 2017-06-30 | 2022-03-14 | Acrotech Biopharma Llc | Nye orale formuleringer af belinostat |
| US20200268788A1 (en) * | 2017-08-28 | 2020-08-27 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| CA3076821A1 (en) * | 2017-09-28 | 2019-04-04 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| KR20200046143A (ko) | 2018-10-15 | 2020-05-07 | 주식회사 아이엠알 | 보안기능이 있는 Pluggable 형태의 IoT 센서 노드 및 게이트웨이 구성 방법 |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| US20240058347A1 (en) * | 2019-10-07 | 2024-02-22 | Viracta Therapeutics, Inc. | Dosages for hdac treatment with reduced side effects |
| JP7495340B2 (ja) * | 2020-12-16 | 2024-06-04 | 株式会社ファンケル | カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法 |
| CN113413389B (zh) * | 2021-07-19 | 2024-03-15 | 成都赜灵生物医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途 |
| WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| CN114558004B (zh) * | 2022-03-29 | 2023-08-11 | 奎马特里克斯有限公司 | Qtx125药物制剂 |
| CN115737549A (zh) * | 2022-11-24 | 2023-03-07 | 北京鑫开元医药科技有限公司 | 一种具有hdac抑制活性的注射液及其制备方法和用途 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025257171A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
| WO2025257173A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
| WO2025257176A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026039412A1 (en) | 2024-08-12 | 2026-02-19 | Genzyme Corporation | Methods and compositions for raav production |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH647412A5 (de) | 1980-03-25 | 1985-01-31 | Hoffmann La Roche | Pharmazeutische praeparate. |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE4010536A1 (de) * | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
| US6071923A (en) | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| KR100475206B1 (ko) | 1995-11-13 | 2005-12-16 | 훽스트 악티엔게젤샤프트 | 사이클릭및헤테로사이클릭N-치환된α-이미노하이드록삼산및카복실산 |
| EP0923932B1 (en) * | 1996-02-26 | 2011-06-29 | Eisai R&D Management Co., Ltd. | Composition containing antitumor agent |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| CZ20011342A3 (cs) | 1998-10-13 | 2001-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Cyklické tetrapeptidy |
| JP2000212088A (ja) * | 1999-01-27 | 2000-08-02 | Kobayashi Kako Kk | 難溶性抗ウイルス剤の水溶液 |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| ES2223705T3 (es) | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
| EP1233958B1 (en) | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
| US6888027B2 (en) | 2000-09-29 | 2005-05-03 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| ATE310719T1 (de) | 2000-09-29 | 2005-12-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| AR035455A1 (es) * | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| WO2002090534A1 (en) | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| BR0211810A (pt) | 2001-08-09 | 2004-08-24 | Ono Pharmaceutical Co | Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo |
| EP1426054B1 (en) | 2001-08-21 | 2011-09-28 | Astellas Pharma Inc. | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US7041699B2 (en) * | 2002-01-11 | 2006-05-09 | Matthias Rath | Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| EP1472216A2 (en) | 2002-02-07 | 2004-11-03 | Axys Pharmaceuticals | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| US20050288227A1 (en) | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| JP2005525345A (ja) | 2002-02-15 | 2005-08-25 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｔｒｘ媒介性疾患を処置する方法 |
| US20070060614A1 (en) | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| AU2003213684C1 (en) | 2002-03-04 | 2008-10-23 | Merck Hdac Research, Llc | Methods of inducing terminal differentiation |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| KR20040090979A (ko) | 2002-03-13 | 2004-10-27 | 얀센 파마슈티카 엔.브이. | 히스톤 데아세틸레이즈의 신규한 억제제 |
| ATE399012T1 (de) | 2002-04-03 | 2008-07-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7495022B2 (en) | 2002-04-11 | 2009-02-24 | Sk Chemicals Co., Ltd. | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
| US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| DE10233412A1 (de) | 2002-07-23 | 2004-02-12 | 4Sc Ag | Neue Verbindungen als Histondeacetylase-Inhibitoren |
| MXPA05001334A (es) | 2002-08-02 | 2005-09-08 | Argenta Discovery Ltd | Acidos tienil-hidroxamicos sustituidos como inhibidores de la desacetilasa de histona. |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| US20080004311A1 (en) | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| ITMI20030025A1 (it) | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | Derivati dell'acido idrossammico ad attivita' antinfiammatoria. |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| WO2004064727A2 (en) | 2003-01-16 | 2004-08-05 | Georgetown University | Method of cancer treatment using hdac inhibitors |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| AU2003900608A0 (en) | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| WO2004074451A2 (en) | 2003-02-18 | 2004-09-02 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
| JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
| TW200424187A (en) | 2003-04-04 | 2004-11-16 | Hoffmann La Roche | New oxime derivatives and their use as pharmaceutically active agents |
| HRP20090487T1 (hr) | 2003-04-07 | 2009-12-31 | Pharmacyclics | Hidroksamati kao terapeutski agensi |
| US20040220242A1 (en) | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| WO2005000901A2 (en) | 2003-05-09 | 2005-01-06 | Duke University | Cd20-specific antibodies and methods of employing same |
| WO2004103358A2 (en) | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| EP1491188A1 (en) | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| PL379887A1 (pl) | 2003-08-26 | 2006-11-27 | Merck Hdac Research, Llc | Sposób leczenia raka inhibitorami HDAC |
| CA2535889A1 (en) | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| JP2007511211A (ja) | 2003-11-14 | 2007-05-10 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| CA2590257A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| WO2005063806A1 (en) | 2003-12-30 | 2005-07-14 | Council Of Scientific And Industrial Research | Arginine hydrochloride enhances chaperone-like activity of alpha crystallin |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| WO2005085864A1 (en) | 2004-02-27 | 2005-09-15 | The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services | Pharmacodynamic assays using flow cytometry |
| SI1591109T1 (sl) | 2004-04-30 | 2008-10-31 | Topotarget Germany Ag | Formulacija, ki obsega inhibitor histon-deacetilaze in izkazuje dvofazno sproščanje |
| WO2005112637A1 (en) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
| DK1781321T3 (da) | 2004-08-02 | 2014-04-14 | Zenyth Operations Pty Ltd | Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist |
| EP1787657A1 (en) | 2004-08-06 | 2007-05-23 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for psychoneurotic disease |
| CN101001851B (zh) | 2004-08-09 | 2011-04-20 | 安斯泰来制药有限公司 | 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物 |
| WO2006060382A2 (en) | 2004-11-30 | 2006-06-08 | Trustees Of The University Of Pennsylvania | Use of hdac and/or dnmt inhibitors for treatment of ischemic injury |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| US20090232800A1 (en) | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2502649A1 (en) | 2005-02-03 | 2012-09-26 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and erlotinib for treating cancer |
| US20060229237A1 (en) | 2005-04-07 | 2006-10-12 | Yih-Lin Chung | Treatment of gastrointestinal distress |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| US20080292616A1 (en) | 2005-08-19 | 2008-11-27 | Government Of The United Of America, Represented By The Secretary, Department Of Health And.... | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same |
| KR20080042170A (ko) | 2005-09-07 | 2008-05-14 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 활성 화합물 |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EA015151B1 (ru) | 2006-02-22 | 2011-06-30 | 4ЭсЦэ АГ | Индолопиридины в качестве модуляторов кинезина eg5 |
| JP5349056B2 (ja) | 2006-02-22 | 2013-11-20 | ４エスツェー アクチェンゲゼルシャフト | Ｅｇ５キネシンモジュレーターとしてのインドロピリジン類 |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| EP1839656A1 (en) | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| US20090142337A1 (en) | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| CA2654566A1 (en) | 2006-06-09 | 2007-12-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| WO2008011603A2 (en) | 2006-07-20 | 2008-01-24 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| WO2008058287A1 (en) | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| US8796330B2 (en) | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| WO2008090534A1 (en) | 2007-01-26 | 2008-07-31 | Berand Limited | Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity |
| US7915245B2 (en) | 2007-02-01 | 2011-03-29 | The Board Of Regents Of The University Of Texas System | Methods and compositions of trail-death receptor agonists/activators |
| US8012695B2 (en) | 2007-02-14 | 2011-09-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to promoter regulation by MUC1 and KLF proteins |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| WO2008154402A2 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US20090246198A1 (en) | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| WO2009137649A2 (en) | 2008-05-07 | 2009-11-12 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
-
2006
- 2006-05-11 AT AT06727086T patent/ATE542527T1/de active
- 2006-05-11 BR BRPI0610128-3A patent/BRPI0610128B1/pt active IP Right Grant
- 2006-05-11 KR KR1020137015868A patent/KR101329437B1/ko not_active Expired - Fee Related
- 2006-05-11 ES ES12151966.4T patent/ES2540204T3/es active Active
- 2006-05-11 CA CA2606598A patent/CA2606598C/en active Active
- 2006-05-11 NZ NZ563236A patent/NZ563236A/en unknown
- 2006-05-11 DK DK12151966.4T patent/DK2494969T3/en active
- 2006-05-11 WO PCT/GB2006/001737 patent/WO2006120456A1/en not_active Ceased
- 2006-05-11 ES ES06727086T patent/ES2380887T3/es active Active
- 2006-05-11 PT PT06727086T patent/PT1901729E/pt unknown
- 2006-05-11 UA UAA200713711A patent/UA99810C2/ru unknown
- 2006-05-11 EA EA201370122A patent/EA023400B1/ru not_active IP Right Cessation
- 2006-05-11 MX MX2007013938A patent/MX2007013938A/es active IP Right Grant
- 2006-05-11 PL PL06727086T patent/PL1901729T3/pl unknown
- 2006-05-11 CN CN201210004670.1A patent/CN102579417B/zh not_active Expired - Fee Related
- 2006-05-11 SI SI200631312T patent/SI1901729T1/sl unknown
- 2006-05-11 CN CN2006800199663A patent/CN101189003B/zh active Active
- 2006-05-11 EA EA200702467A patent/EA018982B1/ru unknown
- 2006-05-11 ZA ZA200710313A patent/ZA200710313B/xx unknown
- 2006-05-11 HR HRP20120341TT patent/HRP20120341T1/hr unknown
- 2006-05-11 KR KR1020077029199A patent/KR101340824B1/ko active Active
- 2006-05-11 DK DK06727086.8T patent/DK1901729T3/da active
- 2006-05-11 AU AU2006245495A patent/AU2006245495B2/en active Active
- 2006-05-11 EP EP12151966.4A patent/EP2494969B1/en active Active
- 2006-05-11 RS RS20120155A patent/RS52214B/sr unknown
- 2006-05-11 US US11/913,191 patent/US8835501B2/en active Active - Reinstated
- 2006-05-11 JP JP2008510642A patent/JP5108750B2/ja active Active
- 2006-05-11 EP EP06727086A patent/EP1901729B1/en active Active
-
2007
- 2007-11-08 IL IL187231A patent/IL187231A/en active IP Right Grant
- 2007-12-10 NO NO20076366A patent/NO339954B1/no unknown
- 2007-12-11 EC EC2007008002A patent/ECSP078002A/es unknown
-
2012
- 2012-03-16 CY CY20121100282T patent/CY1112498T1/el unknown
- 2012-06-06 JP JP2012128900A patent/JP5567068B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-15 IL IL224229A patent/IL224229A/en not_active IP Right Cessation
-
2014
- 2014-08-05 US US14/451,928 patent/US9856211B2/en active Active
-
2017
- 2017-11-15 US US15/813,582 patent/US9957227B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL187231A0 (en) | Pharmaceutical formulations of hdac inhibitors | |
| BR0308908A (pt) | Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase | |
| WO2007109178A3 (en) | Indole derivatives as inhibitors of histone deacetylase | |
| WO2009129335A3 (en) | Selective inhibitors of histone deacetylase | |
| WO2005086898A3 (en) | Inhibitors of histone deacetylase | |
| NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
| MX2014007969A (es) | Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8. | |
| WO2010011296A3 (en) | Deacetylase inhibitors and uses thereof | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| ZA202004023B (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| WO2006017214A3 (en) | Inhibitors of histone deacetylase | |
| WO2020024017A9 (en) | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | |
| TW200745047A (en) | Heterocyclic compounds | |
| UA98757C2 (ru) | Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов | |
| CY1111899T1 (el) | Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης | |
| WO2006063294A3 (en) | Novel inhibitors of histone deacetylase for the treatment of disease | |
| WO2007024574A3 (en) | Topical formulations of histone deacetylase inhibitors and methods of using the same | |
| PH12021550093A1 (en) | Compounds for use in the treatment of fascioliasis | |
| CL2008001553A1 (es) | Uso de inhibidores de desacetilasa de histona para el tratamiento de la destrucción osea causada por enfermedades proliferativas, inflamatorias o por osteoporosis. | |
| TW200637824A (en) | Benzamide derivatives | |
| EA201201529A1 (ru) | Комбинация ингибиторов ксантиноксидазы и статинов и ее применение |